MRNA Moderna Inc
Company Analysis
Latest News
🟢 Moderna is trading 4.09% up today after FDA approval of first mRNA flu vaccine
Moderna is trading 4.09% up now at $63.05 after renewed attention to the FDA’s approval of mFlusiva, its first mRNA-based seasonal flu vaccine. - Approved for...
🟢 Moderna is trading 4.3% up in pre-market after FDA approval of mFLUSIVA
Moderna is trading at $61.70, up +4.28%, after the FDA approved mFLUSIVA, its first mRNA-based seasonal flu vaccine. - The approval covers adults aged 50 and...
Moderna's First mRNA Flu Shot Clears the FDA — But Can It Actually Crack a Market Dominated by Entrenched Giants?
Shares surged +6.2% to $57.19 after the FDA approved Moderna's seasonal mRNA flu vaccine for adults 50 and older — the first influenza shot ever built on mRNA...
🟢 Moderna is trading 6.3% up today after FDA approves mFlusiva
Moderna is trading at $57.19, up +6.26%, on August 7, 2026, after the FDA approved mFlusiva, its seasonal mRNA flu vaccine for adults aged 50 and older. - The...
🔴 Moderna is trading 4.1% down today despite FDA approval for mFLUSIVA
Moderna is trading at $53.95, with a -4.10% change (4.1% down) on August 6, 2026, despite FDA approval of its mFLUSIVA seasonal flu vaccine. - The approval...
🟢 Moderna is trading 4% up today on mRNA flu vaccine FDA focus and improved cost controls
Moderna is trading 4% up at $58.53 in pre-market as traders focus on the upcoming FDA decision for its mRNA-1010 flu vaccine and recently improved Q2 cost...
🟢 Moderna is trading 4.04% up today on mRNA-1010 flu vaccine FDA decision date
Moderna is trading at $59.30 (+4.04%) as investors focus on the upcoming FDA decision date for its mRNA-1010 flu vaccine. • The stock is also supported by...
🟢 Moderna is trading 4.1% up today ahead of Aug 5 FDA flu vaccine decision
Moderna is trading 4.1% up today at $57.41, rebounding from recent post-earnings volatility as the broader biotech sector rallies. • Investors are positioning...
🟢 Moderna is trading 4.1% up today as shares stabilize following last week's earnings-driven selloff
Moderna is trading 4.07% up now at $57.05 as shares stabilize following last week’s earnings-driven selloff and norovirus trial disappointment. • Investors...
Moderna Posts $782 Million Loss, Hit by $950 Million Patent Settlement
Moderna reported a net loss of $782 million for the second quarter of 2026. Revenue for the period totaled $145 million. This revenue figure remained roughly...
🔴 Moderna is trading 4.6% down today after norovirus vaccine setback outweighs Q2 revenue beat
Moderna is trading 4.6% down now at $55.28 as investors focus on a Phase 3 norovirus vaccine setback that overshadowed a second-quarter revenue beat. • The...
🔴 Moderna is trading 4.5% down today after norovirus vaccine failure and Q2 earnings
Moderna is trading 4.5% down at $55.30 after the company reported Q2 2026 earnings and a clinical setback for its norovirus vaccine candidate. • The company...
Moderna's second quarter revenue of $145 million beats estimates amid a key pipeline setback.
Moderna reported second quarter 2026 revenue of $145 million, up from $142 million in the prior-year period, alongside a net loss per share of $1.97, an...
🟢 Moderna is trading 4.1% up today ahead of Q2 earnings and RSV vaccine traction
Moderna is trading 4.1% up at $60.27 as investors position ahead of its Q2 2026 earnings report on July 31 and monitor early traction for its RSV vaccine,...
🟢 Moderna is trading 4% up today ahead of Q2 earnings and RSV vaccine traction
Moderna is trading 4% up today at $56.68 as investors position ahead of its Q2 2026 earnings report on July 31 and focus on early commercial traction for its...
Moderna Inc Q2 2026 Earnings Preview: What Analysts Expect on July 31, 2026
Moderna is expected to report Q2 2026 revenue of $103.1 million and an EPS loss of $1.97, with its current share price of $55.63 trading above the average...
🟢 Moderna rises 4.3% — Biotech Sector Rallies on Blockbuster M&A Deal and Positive Trial Data
With Biotech (XBI) up 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is experiencing a significant...
🔴 Moderna is trading 4.2% down today amid broader biotech and risk-off pressure
Moderna is trading 4.2% down today at $54.65 amid broader biotech weakness and risk-off sentiment. • The decline extends a multi-session slide for the stock,...
Moderna Flu Vaccine Outperforms Standard Shots, Sustaining Immune Response for Six Months
Moderna’s investigational flu vaccine, mRNA-1010, produces a broader and more durable antibody response than conventional shots. A study in Nature Immunology...
Moderna Alleges Breach of Agreement in COVID-19 Vaccine Patent Lawsuit with CureVac
Moderna countered a patent-infringement lawsuit from CureVac. Moderna claims the legal action violates a prior agreement between the two biotech firms. In a...